Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

NCT06445075 on ClinicalTrials.gov · last registry update 2026-01-23

Finished 4 March 2025, after enrolling 102 people. Primary outcome, as filed: Change from Baseline in total Lean Body Mass (kg) at 24 weeks. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Scholar Rock, Inc.
Sponsor type: Industry
Enrollment: 102
Started: 2024-05-21
Primary completion: 2025-03-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline in total Lean Body Mass (kg) at 24 weeks

Conditions studied

Overweight and Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.